Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.
Tips for optimizing an advanced prostate cancer clinic
November 11th 2022In an interview during the 2022 LUGPA Annual Meeting, Jason M. Hafron, MD, shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer treatment in 2022, and discussed how Jelmyto treatment for UTUC has evolved over time.
LuPSMA has similar OS, better patient-reported outcomes than cabazitaxel in mCRPC
June 5th 2022“The clinical implications are that lutetium PSMA has similar overall survival to cabazitaxel, a proven life-prolonging therapy, but with fewer adverse events and better patient-reported outcomes," said Michael S. Hoffman, MBBS (Hons), FRACP, FAANMS.
Significant benefit not seen with maintenance cabozantinib in advanced urothelial carcinoma
June 4th 2022"This study does not support further investigation of cabozantinib alone as a maintenance therapy after platinum-based chemotherapy in unselected patients with advanced urothelial cancer,” said Robert J. Jones, MA, PhD, MBChB.
Low-power thulium laser enucleation of the prostate found efficacious in prostates larger than 80 mL
May 15th 2022“Our results showed significant improvement in postoperative urgency and UUI (P = .005) with no significant change in IIEF-5 score at 6-month follow-up compared to baseline,” wrote the authors.
How onabotulinumtoxinA “revolutionized” treatment of urologic conditions
February 16th 2022In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the significance of onabotulinumtoxinA treatment in patients with overactive bladder.